i've not seen the company's reported figure. I'm basing this on the size and duration of the study as I believe it will be conducted. The retrophin full term primary endpoint is at 104 week (I may remember incorrectly but it's ~100 weeks). It sounds highly ambitious to get that done for 20m. Take a look online, I'm sure someone has done an analysis of Ph3 study costs. Would of course be great to be so cheap but I can't see sub 50m being feasible
Ann: Dimerix Confirms Phase 3 FSGS Study Design With EMA, page-15
-
- There are more pages in this discussion • 26 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
51.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $280.6M | |||
| Open | High | Low | Value | Volume |
| 51.5¢ | 54.5¢ | 51.0¢ | $1.715M | 3.301M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 365433 | 51.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 51.5¢ | 19658 | 1 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| DXB (ASX) Chart |